PMID- 37745252
OWN - NLM
STAT- Publisher
LR  - 20230926
IS  - 1664-042X (Print)
IS  - 1664-042X (Electronic)
IS  - 1664-042X (Linking)
VI  - 14
DP  - 2023
TI  - Exosomes as biomarkers and therapy in type 2 diabetes mellitus and associated 
      complications.
PG  - 1241096
LID - 10.3389/fphys.2023.1241096 [doi]
LID - 1241096
AB  - Type 2 diabetes mellitus (T2DM) is one of the most prevalent metabolic disorders 
      worldwide. However, T2DM still remains underdiagnosed and undertreated resulting 
      in poor quality of life and increased morbidity and mortality. Given this ongoing 
      burden, researchers have attempted to locate new therapeutic targets as well as 
      methodologies to identify the disease and its associated complications at an 
      earlier stage. Several studies over the last few decades have identified 
      exosomes, small extracellular vesicles that are released by cells, as pivotal 
      contributors to the pathogenesis of T2DM and its complications. These discoveries 
      suggest the possibility of novel detection and treatment methods. This review 
      provides a comprehensive presentation of exosomes that hold potential as novel 
      biomarkers and therapeutic targets. Additional focus is given to characterizing 
      the role of exosomes in T2DM complications, including diabetic angiopathy, 
      diabetic cardiomyopathy, diabetic nephropathy, diabetic peripheral neuropathy, 
      diabetic retinopathy, and diabetic wound healing. This study reveals that the 
      utilization of exosomes as diagnostic markers and therapies is a realistic 
      possibility for both T2DM and its complications. However, the majority of the 
      current research is limited to animal models, warranting further investigation of 
      exosomes in clinical trials. This review represents the most extensive and 
      up-to-date exploration of exosomes in relation to T2DM and its complications.
CI  - Copyright (c) 2023 Satyadev, Rivera, Nikolov and Fakoya.
FAU - Satyadev, Nihal
AU  - Satyadev N
AD  - Department of Neurology, Mayo Clinic Florida, Jacksonville, FL, United States.
FAU - Rivera, Milagros I
AU  - Rivera MI
AD  - University of Medicine and Health Sciences, Basseterre, St. Kitts and Nevis.
FAU - Nikolov, Nicole K
AU  - Nikolov NK
AD  - Ross University School of Medicine, Bridgetown, Barbados.
FAU - Fakoya, Adegbenro O J
AU  - Fakoya AOJ
AD  - Louisiana State University Health Sciences Center, Shreveport, LA, United States.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230908
PL  - Switzerland
TA  - Front Physiol
JT  - Frontiers in physiology
JID - 101549006
PMC - PMC10515224
OTO - NOTNLM
OT  - biomarkers
OT  - diabetic cardiomyopathy
OT  - diabetic nephropathy
OT  - diabetic neuropathy
OT  - diabetic retinopathy
OT  - exosomes
OT  - type 2 diabetes mellitus
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/09/25 06:41
MHDA- 2023/09/25 06:41
PMCR- 2023/09/08
CRDT- 2023/09/25 04:57
PHST- 2023/06/16 00:00 [received]
PHST- 2023/08/23 00:00 [accepted]
PHST- 2023/09/25 06:41 [medline]
PHST- 2023/09/25 06:41 [pubmed]
PHST- 2023/09/25 04:57 [entrez]
PHST- 2023/09/08 00:00 [pmc-release]
AID - 1241096 [pii]
AID - 10.3389/fphys.2023.1241096 [doi]
PST - epublish
SO  - Front Physiol. 2023 Sep 8;14:1241096. doi: 10.3389/fphys.2023.1241096. 
      eCollection 2023.